Palliative care in gynecologic oncology

American Journal of Hospice and Palliative Medicine

Volumn 28, Issue 5, 2011, Pages 356-374

  Rezk, Youssef ^a   Timmins III, Patrick F ^a   Smith, Howard S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

end of life care; gynecologic malignancies; gynecologic oncology; malignant bowel obstruction; nausea and vomiting; pain; palliative care; quality of life

Indexed keywords

ANOREXIA; ANXIETY; ATTITUDE TO HEALTH; CACHEXIA; COMORBIDITY; CONSTIPATION; CRITICAL ILLNESS; DELIRIUM; DYSPNEA; FATIGUE; FEMALE; FEMALE GENITAL TRACT TUMOR; HOSPICE CARE; HUMAN; INTESTINE OBSTRUCTION; ONCOLOGY; ORGANIZATION AND MANAGEMENT; PALLIATIVE THERAPY; REVIEW;

ANOREXIA; ANXIETY; CACHEXIA; COMORBIDITY; CONSTIPATION; CRITICAL ILLNESS; DELIRIUM; DYSPNEA; FATIGUE; FEMALE; GENITAL NEOPLASMS, FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HOSPICE CARE; HUMANS; INTESTINAL OBSTRUCTION; MEDICAL ONCOLOGY; PALLIATIVE CARE;

EID: 80051629594     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/1049909110392204     Document Type: Review

References (215)

1. Dalrymple JL, Levenback C., Wolf JK, Bodurka DC, Garcia M., Gershenson DM Trends among gynecologic oncology inpatient deaths: is end-of-life care improving? Gynecol Oncol. 2002; 85(2):356-361.
2. von Gruenigen VE, Frasure HE, Reidy AM, Gil KM Clinical disease course during the last year in ovarian cancer. Gynecol Oncol. 2003;90(3):619-624.
3. Emanuel EJ, Young-Xu Y., Levinsky NG, Gazelle G., Saynina O., Ash AS Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med. 2003;138(8):639-643.
4. Zuckerman C., Wollner D. End of life care and decision making: how far we have come, how far we have to go. Hosp J. 1999; 14(3-4):85-107.
5. Cleeland CS Undertreatment of cancer pain in elderly patients. JAMA. 1998;279(23):1914-1915.
6. Berger AM, Shuster JL, Von Roenn JH Principles and Practice of Palliative Care and Supportive Oncology. 3rd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2006.
7. Hanks GW, Cherny NI, Christakis NA, Fallon M., Kaasa S., Portenoy RK Oxford Textbook of Palliative Medicine. 3rd ed. Oxford, England: Oxford University Press; 2009.
8. Tahmasebi M., Yarandi F., Eftekhar Z., Montazeri A., Namazi H. Quality of life in gynecologic cancer patients. Asian Pac J Cancer Prev. 2007;8(4):591-592.
9. Grossman SA, Sheidler VR, Swedeen K., Mucenski J., Piantadosi S. Correlation of patient and caregiver ratings of cancer pain. J Pain Symptom Manage. 1991;6(2):53-57.
10. Newell S., Sanson-Fisher RW, Girgis A., Bonaventura A. How well do medical oncologists' perceptions reflect their patients' reported physical and psychosocial problems? Data from a survey of five oncologists. Cancer. 1998;83(8):1640-1651.
11. Lickiss N., Philip J. Palliative care and pain management. In: Berek JS, Hacker NF, eds. Practical Gynecologic Oncology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005: 835-862.
12. Cleeland CS, Gonin R., Hatfield AK,et al.Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994;330(9): 592-596.
13. Dahl JL, Joranson DE, Engber D., Dosch J. A report on the Wisconsin cancer pain initiative. J Pain Symptom Manage. 1988;3(suppl 1): S2-S5.
14. World Health Organization. Cancer Pain Relief. Geneva, Switzerland: WHO; 1986.
15. Cancer Pain Assessment and Treatment Curriculum Guidelines. The Ad Hoc Committee on Cancer Pain of the American Society of Clinical Oncology. J Clin Oncol. 1992;10(12):1976-1982.
16. Jacox A., Carr DB, Payne R. New clinical-practice guidelines for the management of pain in patients with cancer. N Engl J Med. 1994;330(9):651-655.
17. Benedetti C., Brock C., Cleeland C., Coyle N., Dubé JE, Ferrell B.,et al,National Comprehensive Cancer Network. NCCN Practice Guidelines for cancer pain. Oncology (Williston Park). 2000; 14(11A):135-150.
18. Lickiss JN Approaching cancer pain relief. Eur J Pain. 2001; 5(supplA):S5-S14.
19. Thanapprapasr D., Nartthanarung A., Likttanasombut P.,et al.Bone metastasis in cervical cancer patients over a 10-year period. Int J Gynecol Cancer. 2010;20(3):373-378.
20. Crook J., Rideout E., Browne G. The prevalence of pain complaints in a general population. Pain. 1984;18(3):299-314.
21. Jensen MP, Karoly P., Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain. 1986;27(1): 117-126.
22. Wynne CF, Ling SM, Remsburg R. Comparison of pain assessment instruments in cognitively intact and cognitively impaired nursing home residents. Geriatr Nurs. 2000;21(1):20-23.
23. Bergh I., Sjostrom B., Oden A., Steen B. Assessing pain and pain relief in geriatric patients with non-pathological fractures with different rating scales. Aging. (Milano). 2001;13(5):355-361.
24. Hurley AC, Volicer BJ, Hanrahan PA, Houde S., Volicer L. Assessment of discomfort in advanced Alzheimer patients. Res Nurs Health. 1992;15(5):369-377.
25. Serlin RC, Mendoza TR, Nakamura Y., Edwards KR, Cleeland CS When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995;61(2):277-284.
26. Wenzel L., Huang HQ, Cella D., Walker JL, Armstrong DK Gynecologic Oncology Group. Validation of FACT/GOG-AD sub-scale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;110(1):60-64.
27. Luckett T., King M., Butow P., Friedlander M., Paris T. Assessing health-related quality of life in gynecologic oncology: a systematic review of questionnaires and their ability to detect clinically important differences and change. Int J Gynecol Cancer. 2010; 20(4):664-684.
28. Cherny NI, Foley KM Current approaches to the management of cancer pain: a review. Ann Acad Med Singapore. 1994;23(2): 139-159.
29. Watson CP Antidepressant drugs as adjuvant analgesics. J Pain Symptom Manage. 1994;9(6):392-405.
30. Forrest WH Jr, Brown BW Jr, Brown CR,et al.Dextroamphetamine with morphine for the treatment of postoperative pain. N Engl J Med. 1977;296(13):712-715.
31. Bruera E., Chadwick S., Brenneis C., Hanson J., MacDonald RN Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep. 1987;71(1):67-70.
32. Rumore MM, Schlichting DA Clinical efficacy of antihistaminics as analgesics. Pain. 1986;25(1):7-22.
33. Beaver WT, Wallenstein SL, Houde RW, Rogers A. A comparison of the analgesic effects of methotrimeprazine and morphine in patients with cancer. Clin Pharmacol Ther. 1966;7(4): 436-446.
34. Lipton A., Theriault RL, Hortobagyi GN,et al.Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88(5):1082-1090.
35. Szanto J., Ady N., Jozsef S. Pain killing with calcitonin nasal spray in patients with malignant tumors. Oncology. 1992;49(3):180-182.
36. Ventafridda V., Tamburini M., Caraceni A., De Conno F., Naldi F. A validation study of the WHO method for cancer pain relief. Cancer. 1987;59(4):850-856.
37. Zech DF, Grond S., Lynch J., Hertel D., Lehmann KA Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995;63(1):65-76.
38. Mercadante S. Pain treatment and outcomes for patients with advanced cancer who receive follow-up care at home. Cancer. 1999;85(8):1849-1858.
39. Stevens MJ, Gonet YM Malignant psoas syndrome: recognition of an oncologic entity. Australas Radiol. 1990;34(2):150-154.
40. Rodriguez MJ, Contreras D., Galvez R.,et al.Double-blind evaluation of short-term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain. 2003;104(1-2):103-110.
41. McNicol E., Strassels SA, Goudas L., Lau J., Carr DB NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev. 2005;(1):CD005180.
42. Kearney PM, Baigent C., Godwin J., Halls H., Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302-1308.
43. Kilander A., Dotevall G. Endoscopic evaluation of the comparative effects of acetylsalicylic acid and choline magnesium trisalicylate on human gastric and duodenal mucosa. Br J Rheumatol. 1983; 22(1):36-40.
44. Danesh BJ, Saniabadi AR, Russell RI, Lowe GD Therapeutic potential of choline magnesium trisalicylate as an alternative to aspirin for patients with bleeding tendencies. Scott Med J. 1987; 32(6):167-168.
45. Portenoy RK, Hagen NA Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41(3):273-281.
46. Svendsen KB, Andersen S., Arnason S.,et al.Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain. 2005;9(2): 195-206.
47. Mercadante S., Radbruch L., Caraceni A.,et al.Episodic (breakthrough) pain: consensus conference of an expert working group of the European association for palliative care. Cancer. 2002; 94(3):832-839.
48. Portenoy RK, Payne D., Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81(1-2): 129-134.
49. Caraceni A., Martini C., Zecca E.,et al.Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18(3):177-183.
50. Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain. 2003;101(1-2):55-64.
51. Fine PG, Busch MA Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manage. 1998;16(3):179-183.
52. Bruera E., Schoeller T., Wenk R.,et al.A prospective multicenter assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manage. 1995;10(5):348-355.
53. Mercadante S., Maddaloni S., Roccella S., Salvaggio L. Predictive factors in advanced cancer pain treated only by analgesics. Pain. 1992;50(2):151-155.
54. Fortner BV, Okon TA, Portenoy RK A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain. 2002;3(1):38-44.
55. Portenoy RK, Taylor D., Messina J., Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22(9):805-811.
56. Portenoy RK, Moulin DE, Rogers A., Inturrisi CE, Foley KM I.v. infusion of opioids for cancer pain: clinical review and guidelines for use. Cancer Treat Rep. 1986;70(5):575-581.
57. Mercadante S. Neuraxial techniques for cancer pain: an opinion about unresolved therapeutic dilemmas. Reg Anesth Pain Med. 1999;24(1):74-83.
58. Eisenach JC, DuPen S., Dubois M., Miguel R., Allin D. Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain. 1995;61(3):391-399.
59. Smith HS, Deer TR, Staats PS, Singh V., Sehgal N., Cordner H. Intrathecal drug delivery. Pain Physician. 2008;11(2suppl): S89-S104.
60. Smith HS, Deer TR Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain. Ther Clin Risk Manag. 2009;5(3):521-534.
61. Staats PS, Yearwood T., Charapata SG,et al.Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA. 2004;291(1):63-70.
62. Rauck RL, Wallace MS, Burton AW, Kapural L., North JM Intrathecal ziconotide for neuropathic pain: a review. Pain Pract. 2009;9(5):327-337.
63. de Leon-Casasola OA, Kent E., Lema MJ Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Pain. 1993;54(2):145-151.
64. Eisenberg E., Carr DB, Chalmers TC Neurolytic celiac plexus block for treatment of cancer pain: a meta-analysis. Anesth Analg. 1995;80(2):290-295.
65. de Leon-Casasola OA Critical evaluation of chemical neurolysis of the sympathetic axis for cancer pain. Cancer Control. 2000; 7(2):142-148.
66. Cariati M., De Martini G., Pretolesi F., Roy MT CT-guided superior hypogastric plexus block. J Comput Assist Tomogr. 2002; 26(3):428-431.
67. Christo P., Mazloomdoost D. Interventional pain treatments for cancer pain. Ann N Y Acad Sci. 2008;1138:299-328.
68. Felsoory A., Crue BL Results of 19 years experience with sacral rhizotomy for perineal and perianal cancer pain. Pain. 1976;2(4): 431-433.
69. Nauta HJ, Soukup VM, Fabian RH, Lin JT, Grady JJ, Williams CG,et al.Punctate midline myelotomy for the relief of visceral cancer pain. J Neurosurg. 2000;92(2suppl): S125-S130.
70. Kim YS, Kwon SJ High thoracic midline dorsal column myelotomy for severe visceral pain due to advanced stomach cancer. Neurosurgery. 2000;46(1):85-90.
71. Stuart G., Cramond T. Role of percutaneous cervical cordotomy for pain of malignant origin. Med J Aust. 1993;158(10):667-670.
72. Jones B., Finlay I., Ray A., Simpson B. Is there still a role for open cordotomy in cancer pain management? J Pain Symptom Manage. 2003;25(2):179-184.
73. Crul BJ, Blok LM, van Egmond J., van Dongen RT The present role of percutaneous cervical cordotomy for the treatment of cancer pain. J Headache Pain. 2005;6(1):24-29.
74. Woolf CJ, Mannion RJ Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet. 1999;353(9168): 1959-1964.
75. Grond S., Radbruch L., Meuser T., Sabatowski R., Loick G., Lehmann KA Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain. 1999;79(1):15-20.
76. Mercadante S., Lodi F., Sapio M., Calligara M., Serretta R. Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. J Pain Symptom Manage. 1995;10(7):564-568.
77. Fine PG Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain. J Pain Symptom Manage. 1999; 17(4):296-300.
78. McQueen AL, Baroletti SA Adjuvant ketamine analgesia for the management of cancer pain. Ann Pharmacother. 2002;36(10): 1614-1619.
79. Kedlaya D., Reynolds L., Waldman S. Epidural and intrathecal analgesia for cancer pain. Best Pract Res Clin Anaesthesiol. 2002;16(4):651-665.
80. Agar M., Broadbent A., Chye R. The management of malignant psoas syndrome: case reports and literature review. J Pain Symptom Manage. 2004;28(3):282-293.
81. Breitbart W. Psychiatric management of cancer pain. Cancer. 1989;63(11suppl):S2336-S2342.
82. Fishman B., Loscalzo M. Cognitive-behavioral interventions in management of cancer pain: principles and applications. Med Clin North Am. 1987;71(2):271-287.
83. Malseed RT, Goldstein FJ Enhancement of morphine analgesia by tricyclic antidepressants. Neuropharmacology. 1979;18(10): 827-829.
84. Spiegel K., Kalb R., Pasternak GW Analgesic activity of tricyclic antidepressants. Ann Neurol. 1983;13(4):462-465.
85. Kaufmann MW, Murray GB, Cassem NH Use of psychostimulants in medically ill depressed patients. Psychosomatics. 1982; 23(8):817-819.
86. Fernandez F., Adams F., Holmes VF, Levy JK, Neidhart M. Methylphenidate for depressive disorders in cancer patients. An alternative to standard antidepressants. Psychosomatics. 1987; 28(9):455-461.
87. Murata H. Spiritual pain and its care in patients with terminal cancer: construction of a conceptual framework by philosophical approach. Palliat Support Care. 2003;1(1):15-21.
88. Storey P. Spiritual care at the end of life. Tex Med. 2001;97(8): 56-59.
89. Lee HR, Lennon VA, Camilleri M., Prather CM Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol. 2001;96(2): 373-379.
90. Tunca JC, Buchler DA, Mack EA, Ruzicka FF, Crowley JJ, Carr WF The management of ovarian-cancer-caused bowel obstruction. Gynecol Oncol. 1981;12(2pt1):186-192.
91. Clarke-Pearson DL, Chin NO, DeLong ER, Rice R., Creasman WT Surgical management of intestinal obstruction in ovarian cancer. I. Clinical features, postoperative complications, and survival. Gynecol Oncol. 1987;26(1):11-18.
92. Ripamonti C., Panzeri C., Groff L., Galeazzi G., Boffi R. The role of somatostatin and octreotide in bowel obstruction: pre-clinical and clinical results. Tumori. 2001;87(1):1-9.
93. Ripamonti C., Twycross R., Baines M.,et al,Working Group of the European Association for Palliative Care. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer. 2001; 9(4):223-233.
94. Ripamonti C., De Conno F., Ventafridda V., Rossi B., Baines MJ Management of bowel obstruction in advanced and terminal cancer patients. Ann Oncol. 1993;4(1):15-21.
95. Butler JA, Cameron BL, Morrow M., Kahng K., Tom J. Small bowel obstruction in patients with a prior history of cancer. Am J Surg. 1991;162(6):624-628.
96. Ripamonti C., Bruera E. Palliative management of malignant bowel obstruction. Int J Gynecol Cancer. 2002;12(2): 135-143.
97. Lund B., Hansen M., Lundvall F., Nielsen NC, Sørensen BL, Hansen HH Intestinal obstruction in patients with advanced carcinoma of the ovaries treated with combination chemotherapy. Surg Gynecol Obstet. 1989;169(3):213-218.
98. Chan A., Woodruff RK Intestinal obstruction in patients with widespread intraabdominal malignancy. J Pain Symptom Manage. 1992;7(6):339-342.
99. Woolfson RG, Jennings K., Whalen GF Management of bowel obstruction in patients with abdominal cancer. Arch Surg. 1997;132(10):1093-1097.
100. Krebs HB, Goplerud DR Surgical management of bowel obstruction in advanced ovarian carcinoma. Obstet Gynecol. 1983;61(3):327-330.
101. Aabo K., Pedersen H., Bach F., Knudsen J. Surgical management of intestinal obstruction in the late course of malignant disease. Acta Chir Scand. 1984;150(2):173-176.
102. Weiss SM, Skibber JM, Rosato FE Bowel obstruction in cancer patients: performance status as a predictor of survival. J Surg Oncol. 1984;25(1):15-17.
103. Gallick HL, Weaver DW, Sachs RJ, Bouwman DL Intestinal obstruction in cancer patients. An assessment of risk factors and outcome. Am Surg. 1986;52(8):434-437.
104. Clarke-Pearson DL, DeLong ER, Chin N., Rice R., Creasman WT Intestinal obstruction in patients with ovarian cancer. Variables associated with surgical complications and survival. Arch Surg. 1988;123(1):42-45.
105. Fernandes JR, Seymour RJ, Suissa S. Bowel obstruction in patients with ovarian cancer: a search for prognostic factors. Am J Obstet Gynecol. 1988;158(2):244-249.
106. Larson JE, Podczaski ES, Manetta A., Whitney CW, Mortel R. Bowel obstruction in patients with ovarian carcinoma: analysis of prognostic factors. Gynecol Oncol. 1989;35(1): 61-65.
107. Rubin SC, Hoskins WJ, Benjamin I., Lewis JL Jr. Palliative surgery for intestinal obstruction in advanced ovarian cancer. Gynecol Oncol. 1989;34(1):16-19.
108. van Ooijen B., van der Burg ME, Planting AS, Siersema PD, Wiggers T. Surgical treatment or gastric drainage only for intestinal obstruction in patients with carcinoma of the ovary or peritoneal carcinomatosis of other origin. Surg Gynecol Obstet. 1993;176(5):469-474.
109. Zoetmulder FA, Helmerhorst TJ, van Coevorden F., Wolfs PE, Leyer JP, Hart AA Management of bowel obstruction in patients with advanced ovarian cancer. Eur J Cancer. 1994;30A(11): 1625-1628.
110. Feuer DJ, Broadley KE, Shepherd JH, Barton DP Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2000;(4):CD002764.
111. Scott-Mackie P., Morgan R., Farrugia M., Glynos M., Adam A. The role of metallic stents in malignant duodenal obstruction. Br J Radiol. 1997;70(831):252-255.
112. Pinto IT Malignant gastric and duodenal stenosis: palliation by peroral implantation of a self-expanding metallic stent. Cardiovasc Intervent Radiol. 1997;20(6):431-434.
113. Park HS, Do YS, Suh SW,et al.Upper gastrointestinal tract malignant obstruction: initial results of palliation with a flexible covered stent. Radiology. 1999;210(3):865-870.
114. de Gregorio MA, Mainar A., Tejero E.,et al.Acute colorectal obstruction: stent placement for palliative treatment-results of a multicenter study. Radiology. 1998;209(1):117-120.
115. Baron TH, Kozarek RA Endoscopic stenting of colonic tumours. Best Pract Res Clin Gastroenterol. 2004;18(1):209-229.
116. Baron TH Colonic stenting: technique, technology, and outcomes for malignant and benign disease. Gastrointest Endosc Clin N Am. 2005;15(4):757-771.
117. Caceres A., Zhou Q., Iasonos A., Gerdes H., Chi DS, Barakat RR Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series. Gynecol Oncol. 2008;108(3):482-485.
118. Stellato TA, Gauderer MW Percutaneous endoscopic gastrostomy for gastrointestinal decompression. Ann Surg. 1987; 205(2):119-122.
119. Herman LL, Hoskins WJ, Shike M. Percutaneous endoscopic gastrostomy for decompression of the stomach and small bowel. Gastrointest Endosc. 1992;38(3):314-318.
120. Cunningham MJ, Bromberg C., Kredentser DC, Collins MB, Malfetano JH Percutaneous gastrostomy for decompression in patients with advanced gynecologic malignancies. Gynecol Oncol. 1995;59(2):273-276.
121. Campagnutta E., Cannizzaro R., Gallo A.,et al.Palliative treatment of upper intestinal obstruction by gynecological malignancy: the usefulness of percutaneous endoscopic gastrostomy. Gynecol Oncol. 1996;62(1):103-105.
122. Moller P., Lindberg CG, Zilling T. Gastrostomy by various techniques: evaluation of indications, outcome, and complications. Scand J Gastroenterol. 1999;34(10):1050-1054.
123. Pothuri B., Montemarano M., Gerardi M.,et al.Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol. 2005;96(2):330-334.
124. Picus D., Marx MV, Weyman PJ Chronic intestinal obstruction: value of percutaneous gastrostomy tube placement. AJR Am J Roentgenol. 1988;150(2):295-297.
125. Forgacs I., Macpherson A., Tibbs C. Percutaneous endoscopic gastrostomy. BMJ. 1992;304(6839):1395-1396.
126. Chi DS, Phaëton R., Miner TJ,et al.A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer. Oncologist. 2009;14(8):835-839.
127. Baines M., Oliver DJ, Carter RL Medical management of intestinal obstruction in patients with advanced malignant disease. A clinical and pathological study. Lancet. 1985;2(8462):990-993.
128. Ventafridda V., Ripamonti C., Caraceni A., Spoldi E., Messina L., De Conno F. The management of inoperable gastrointestinal obstruction in terminal cancer patients. Tumori. 1990;76(4):389-393.
129. De Conno F., Caraceni A., Zecca E., Spoldi E., Ventafridda V. Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Symptom Manage. 1991;6(8):484-486.
130. Davis MP, Furste A. Glycopyrrolate: a useful drug in the palliation of mechanical bowel obstruction. J Pain Symptom Manage. 1999;18(3):153-154.
131. Ripamonti C., Mercadante S., Groff L., Zecca E., De Conno F., Casuccio A. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage. 2000;19(1):23-34.
132. Mercadante S., Ripamonti C., Casuccio A., Zecca E., Groff L. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer. 2000;8(3):188-191.
133. Twycross R. Corticosteroids in advanced cancer. BMJ. 1992; 305(6860):969-970.
134. Philip J., Lickiss N., Grant PT, Hacker NF Corticosteroids in the management of bowel obstruction on a gynecological oncology unit. Gynecol Oncol. 1999;74(1):68-73.
135. Feuer DJ, Broadley KE Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2000;(2): CD001219.
136. Mercadante S. The role of octreotide in palliative care. J Pain Symptom Manage. 1994;9(6):406-411.
137. Penn RD, Paice JA, Kroin JS Octreotide: a potent new non-opiate analgesic for intrathecal infusion. Pain. 1992;49(1): 13-19.
138. Paice JA, Penn RD, Kroin JS Intrathecal octreotide for relief of intractable nonmalignant pain: 5-year experience with two cases. Neurosurgery. 1996;38(1):203-207.
139. Mulvihill SJ, Pappas TN, Fonkalsrud EW, Debas HT The effect of somatostatin on experimental intestinal obstruction. Ann Surg. 1988;207(2):169-173.
140. Gittes GK, Nelson MT, Debas HT, Mulvihill SJ Improvement in survival of mice with proximal small bowel obstruction treated with octreotide. Am J Surg. 1992;163(2):231-233.
141. Cullen JJ, Eagon JC, Kelly KA Gastrointestinal peptide hormones during postoperative ileus. Effect of octreotide. Dig Dis Sci. 1994;39(6):1179-1184.
142. Yamaner S., Bugra D., Muslumanoglu M., Bulut T., Cubukçu O., Ademoǧlu E. Effects of octreotide on healing of intestinal anastomosis following small bowel obstruction in rats. Dis Colon Rectum. 1995;38(3):308-312.
143. Guiro FF, Bertolini G., Salas JV Improvement in the intestinal processes of hydroelectrolytic absorption and secretion in abdominal pathologies of surgical interest treated with SMS 201-995: experimental protocol. Surg Today. 1999;29(5): 419-430.
144. Khoo D., Riley J., Waxman J. Control of emesis in bowel obstruction in terminally ill patients. Lancet. 1992;339(8789):375-376.
145. Mercadante S., Maddaloni S. Octreotide in the management of inoperable gastrointestinal obstruction in terminal cancer patients. J Pain Symptom Manage. 1992;7(8):496-498.
146. Mercadante S., Spoldi E., Caraceni A., Maddaloni S., Simonetti MT Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med. 1993;7(4):295-299.
147. Mangili G., Franchi M., Mariani A., Zanaboni F., Rabaiotti E., Frigerio L.,et al.Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecol Oncol. 1996; 61(3):345-348.
148. Mystakidou K., Tsilika E., Kalaidopoulou O., Chondros K., Georgaki S., Papadimitriou L. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double-blind, controlled clinical trial. Anticancer Res. 2002;22(2B):1187-1192.
149. Matulonis UA, Seiden MV, Roche M.,et al.Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manage. 2005;30(6):563-569.
150. Fainsinger RL, MacEachern T., Miller MJ,et al.The use of hypodermoclysis for rehydration in terminally ill cancer patients. J Pain Symptom Manage. 1994;9(5):298-302.
151. Lanuke K., Fainsinger RL, DeMoissac D. Hydration management at the end of life. J Palliat Med. 2004;7(2):257-263.
152. Glare P., Lickiss JN Unrecognized constipation in patients with advanced cancer: a recipe for therapeutic disaster. J Pain Symptom Manage. 1992;7(6):369-371.
153. Kalso E., Edwards JE, Moore RA, McQuay HJ Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372-380.
154. Walsh TD Oral morphine in chronic cancer pain. Pain. 1984; 18(1):1-11.
155. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(5Asuppl): 11S-18S.
156. McNicol E., Horeowicz-Mehler N., Fisk RA,et al.Management of opioid side effects in cancer-related and chronic non-cancer pain: a systematic review. J Pain. 2003;4(5):231-256.
157. Bell TJ, Panchal SJ, Miaskowski C., Bolge SC, Milanova T., Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1). Pain Med. 2009;10(1):35-42.
158. Neary P., Delaney CP Alvimopan. Expert Opin Investig Drugs. 2005;14(4):479-488.
159. McNicol ED, Boyce D., Schumann R., Carr DB Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst Rev. 2008;(2):CD006332.
160. Thomas J., Karver S., Cooney GA,et al.Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332-2343.
161. Yuan CS, Israel RJ Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side-effects. Expert Opin Investig Drugs. 2006;15(5):541-552.
162. De Ponti F. Methylnaltrexone. Curr Opin Investig Drugs. 2002; 3(4):614-620.
163. Earnshaw SR, Klok RM, Iyer S., McDade C. Methylnaltrexone bromide for the treatment of opioid-induced constipation in patients with advanced illness: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2010;31(8):911-921.
164. Kinghorn S. Palliative care. Nausea and vomiting. Nurs Times. 1997;93(33):57-60.
165. Axelrod RS Antiemetic therapy. Compr Ther. 1997;23(8): 539-545.
166. Lichter I. Which antiemetic? J Palliat Care. 1993;9(1):42-50.
167. Dickerson D. The 20 essential drugs in palliative care. Eur J Palliat Care. 1999;6(4):130-135.
168. Loprinzi CL, Kugler JW, Sloan JA,et al.Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol. 1999;17(10):3299-3306.
169. Della Cuna GR, Pellegrini A., Piazzi M. Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group. Eur J Cancer Clin Oncol. 1989;25(12):1817-1821.
170. Twycross R., Back I. Nausea and vomiting in advanced cancer. Eur J Palliat Care. 1998;5(2):39-45.
171. Cole RM, Robinson F., Harvey L., Trethowan K., Murdoch V. Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer. J Pain Symptom Manage. 1994;9(1): 48-50.
172. Mystakidou K., Befon S., Liossi C., Vlachos L. Comparison of tropisetron and chlorpromazine combinations in the control of nausea and vomiting of patients with advanced cancer. J Pain Symptom Manage. 1998;15(3):176-184.
173. Lane M., Vogel CL, Ferguson J.,et al.Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage. 1991; 6(6):352-359.
174. Smyth JF, Coleman RE, Nicolson M.,et al.Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? BMJ. 1991;303(6815):1423-1426.
175. Bruera ED, Roca E., Cedaro L., Chacon R., Estevez R. Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide. Cancer Treat Rep. 1983;67(4):381-383.
176. Bruera E., Seifert L., Watanabe S.,et al.Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. J Pain Symptom Manage. 1996;11(3):147-153.
177. Silvey L., Carpenter JT Jr, Wheeler RH, Lee J., Conolley C. A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer. J Clin Oncol. 1988;6(9):1397-1400.
178. Oliver DJ The use of methotrimeprazine in terminal care. Br J Clin Pract. 1985;39(9):339-340.
179. Twycross R., Barkby G., Hallwood P. The use of low dose methotrimeprazine (levopromazine) in the management of nausea and vomiting. Prog Palliat Care. 1997;5(2):49-53.
180. O'Neill J., Fountain A. Levomepromazine (methotrimeprazine) and the last 48 hours. Hosp Med. 1999;60(8):564-567.
181. Oechsle K., Müller MR, Hartmann JT, Kanz L., Bokemeyer C. Aprepitant as salvage therapy in patients with chemotherapy-induced nausea and emesis refractory to prophylaxis with 5-HT(3) antagonists and dexamethasone. Onkologie. 2006; 29(12):557-561.
182. Rapoport BL, Jordan K., Boice JA,et al.Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2010;18(4):423-431.
183. Seligman PA, Fink R., Massey-Seligman EJ Approach to the seriously ill or terminal cancer patient who has a poor appetite. Semin Oncol. 1998;25(2suppl6):S33-S34.
184. Eldridge B., Rock CL, McCallum PD Nutrition and the patient with cancer. In: Coulston AM, Rock CL, Monsen ER, eds. Nutrition in the Prevention and Treatment of Disease. San Diego, CA: Academic Press; 2001:397-412.
185. Position of The American Dietetic Association: issues in feeding the terminally ill adult. J Am Diet Assoc. 1992;92(8):996-1002.
186. Bruera E., Macmillan K., Kuehn N., Hanson J., MacDonald RN A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer. 1990;66(6):1279-1282.
187. Loprinzi CL, Ellison NM, Schaid DJ, Krook JE, Athmann LM, Dose AM,et al.Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst. 1990;82(13):1127-1132.
188. Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2005 (2): CD004310.
189. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer. 1974; 33(6):1607-1609.
190. Willox JC, Corr J., Shaw J., Richardson M., Calman KC, Drennan M. Prednisolone as an appetite stimulant in patients with cancer. Br Med J (Clin Res Ed). 1984;288(6410):27.
191. Bruera E., Roca E., Cedaro L., Carraro S., Chacon R. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep. 1985; 69(7-8):751-754.
192. Popiela T., Lucchi R., Giongo F. Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group. Eur J Cancer Clin Oncol. 1989;25(12):1823-1829.
193. Argiles JM, Meijsing SH, Pallares-Trujillo J., Guirao X., Lopez-Soriano FJ Cancer cachexia: a therapeutic approach. Med Res Rev. 2001;21(1):83-101.
194. Tchekmedyian NS, Halpert C., Ashley J., Heber D. Nutrition in advanced cancer: anorexia as an outcome variable and target of therapy. JPEN J Parenter Enteral Nutr. 1992;16(6suppl): S88-S92.
195. Bruera E. Clinical management of anorexia and cachexia in patients with advanced cancer. Oncology. 1992;49(suppl 2): S35-S42.
196. Ottery FD Supportive nutrition to prevent cachexia and improve quality of life. Semin Oncol. 1995;22(suppl 3):S98-S111.
197. Lelli G., Montanari M., Gilli G., Scapoli D., Antonietti C., Scapoli D. Treatment of the cancer anorexia-cachexia syndrome: a critical reappraisal. J Chemother. 2003;15(3):220-225.
198. Mantovani G., Maccio A., Lai P., Massa E., Ghiani M., Santona MC Cytokine activity in cancer-related anorexia/ cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol. 1998;25(suppl 6):S45-S52.
199. Gogos CA, Ginopoulos P., Salsa B., Apostolidou E., Zoumbos NC, Kalfarentzos F. Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial. Cancer. 1998;82(2):395-402.
200. Edelman MJ, Gandara DR, Meyers FJ,et al.Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome. Cancer. 1999;86(4):684-688.
201. Agteresch HJ, Dagnelie PC, van der Gaast A., Stijnen T., Wilson JH Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000;92(4):321-328.
202. Persson C., Glimelius B., Ronnelid J., Nygren P. Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomized pilot study. Nutrition. 2005;21(2):170-178.
203. Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T., Goggin PM Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut. 2005;54(4):540-545.
204. Vigano A., Watanabe S., Bruera E. Anorexia and cachexia in advanced cancer patients. Cancer Surv. 1994;21:99-115.
205. McCann RM, Hall WJ, Groth-Juncker A. Comfort care for terminally ill patients. The appropriate use of nutrition and hydration. JAMA. 1994;272(16):1263-1266.
206. Curtin JP, Burt LL Successful treatment of small intestine fistula with somatostatin analog. Gynecol Oncol. 1990;39(2): 225-227.
207. Sawin SW, Aikins JK, Van Hoeuen KH, Prioleau Y., Morgan MA, Mikuta JJ Recurrent squamous cell carcinoma of the cervix with pulmonary lymphangitic metastasis. Int J Gynaecol Obstet. 1995;48(1):85-90.
208. Boyd KJ, Kelly M. Oral morphine as symptomatic treatment of dyspnoea in patients with advanced cancer. Palliat Med. 1997; 11(4):277-281.
209. Mazzocato C., Buclin T., Rapin CH The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: a randomized double-blind controlled trial. Ann Oncol. 1999;10(12):1511-1514.
210. Thomas JR, von Gunten CF Management of dyspnea. J Support Oncol. 2003;1(1):23-32.
211. Smith P., Bruera E. Management of malignant ureteral obstruction in the palliative care setting. J Pain Symptom Manage. 1995;10(6):481-486.
212. Hamdy FC, Williams JL Use of dexamethasone for ureteric obstruction in advanced prostate cancer: percutaneous nephrostomies can be avoided. Br J Urol. 1995;75(6):782-785.
213. Chye RW, Lickiss JN Palliative care in bilateral malignant ureteric obstruction. Ann Acad Med Singapore. 1994;23(2): 197-203.
214. Berenson JR Treatment of hypercalcemia of malignancy with bisphosphonates. Semin Oncol. 2002;29(suppl 21): S12-S18.
215. Ramondetta LM, Tortolero-Luna G., Bodurka DC,et al.Approaches for end-of-life care in the field of gynecologic oncology: an exploratory study. Int J Gynecol Cancer. 2004;14(4): 580-588.